natgillin/translations-raw huggingface dataset:
It is important for you to practice good mouth care during treatment with COMETRIQ. 
Pomembno je, da med zdravljenjem z zdravilom COMETRIQ vzdržujete dobro ustno higieno.
METHOD AND ROUTE(S) OF ADMINISTRATION Oral use. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA peroralna uporaba.
In rat and dog repeat-dose toxicity studies up to 6 months duration, target organs for toxicity were GI tract, bone marrow, lymphoid tissues, kidney, adrenal and reproductive tract tissues. 
V študijah toksičnosti pri ponavljajočih se odmerkih pri podganah in psih, ki so trajale do 6 mesecev, so bili ciljni organi za toksičnost prebavila, kostni mozeg, limfoidno tkivo, ledvice, tkivo nadledvične žleze in rodil.
• Pain in the arms, hands, legs or feet 
• bolečine v rokah, dlaneh, nogah ali stopalih
• Inflammation at the root of your hair, acne, blisters (on parts of your body other than the hands or feet) 
• vnetje lasne korenine, akne, mehurji (na delih telesa, razen dlaneh in stopalih)
You should not take COMETRIQ with food. 
Zdravila COMETRIQ ne smete jemati s hrano.
What you need to know before you take COMETRIQ 
Kaj morate vedeti, preden boste vzeli zdravilo COMETRIQ
• Chest pain due to blockage in arteries, rapid heartbeat 
• bolečina v prsih zaradi blokade arterij, hiter srčni utrip
Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication. 
Z uporabo kabozantiniba je treba prenehati pri bolnikih, pri katerih se razvije akutni miokardni infarkt ali drugi klinično pomembni zapleti arterijske trombembolije.
• Hair colour changes (lightening), hair loss 
• spremenjena barva last (posvetlitev), izpadanje las
How to take COMETRIQ 4. 
Kako jemati zdravilo COMETRIQ 4.
Cabozantinib was an inhibitor (IC50 = 7.0 μM), but not a substrate, of P-glycoprotein (P-gp) transport activities in a bi-directional assay system using MDCK-MDR1 cells. 
Kabozantinib je bil zaviralec (IC50 = 7,0 μM), ne pa tudi substrat prenašalskih aktivnosti Pglikoproteina (P-gp) v sistemu dvosmernega testa z uporabo celic MDCK-MDR1.
three grey 20 mg 
tri sive 20 mg
A thyroid stimulating hormone (TSH) value above normal after first dose was observed in 57% of patients on cabozantinib versus 19% of patients on placebo (regardless of baseline values). 
Pri 57 % bolnikov, ki so uporabljali kabozantinib, so po prvem odmerku opazili vrednosti tiroideo stimulirajočega hormona (TSH) nad normalnimi v primerjavi z 19 % bolniki, ki so dobivali placebo (neodvisno od vrednosti ob izhodišču).
The no observed adverse effect level (NOAEL) for these findings were below human clinical exposure levels at intended therapeutic dose. 
Raven brez opaženega neželenega učinka (NOAEL, no observed adverse effect level) za te izsledke je bila pod ravnmi klinične izpostavljenosti pri nameravanih terapevtskih odmerkih pri ljudeh.
Therefore, concomitant use of MRP2 inhibitors (e.g. cyclosporine, efavirenz, emtricitabine) should be approached with caution. 
Zato je potrebna pri sočasni uporabi zaviralcev MRP2 (npr. ciklosporina, efavirenza, emtricitabina) previdnost.
Cabozantinib should not be administered to patients with serious haemorrhage or recent haemoptysis. 
Kabozantiniba se ne sme dajati bolnikom s hudo krvavitvijo ali nedavno hemoptizo.
Each blister card contains enough medicine for 7 days. 
Ena pretisna zgibanka vsebuje dovolj zdravila za 7 dni.
Blister cards containing: 
Pretisna zgibanka, ki vsebuje:
Talk to your doctor BEFORE taking COMETRIQ if you or your partner are considering or planning to have a baby after your treatment has finished. 
PRED uporabo zdravila COMETRIQ se posvetujte z zdravnikom, če vi ali vaša partnerica po koncu zdravljenja razmišljate o zanositvi ali jo načrtujete.
Women of childbearing potential/Contraception in males and females Women of childbearing potential must be advised to avoid pregnancy while on cabozantinib. 
Ženske v rodni dobi / kontracepcija pri moških in ženskah Ženskam v rodni dobi je treba svetovati, da v času zdravljenja s kabozantinibom ne smejo zanositi.
The final analysis of OS was conducted after 218 events (deaths) occurred and shows a trend for an increase in median survival of 5.5 months in the cabozantinib arm: median (months) 26.6 cabozantinib vs. 21.1 placebo (HR = 0.85 [95% CI: 0.64, 1.12], p = 0.2409). 
Končna analiza OS je bila izvedena po 218 dogodkih (smrtih) in kaže trend za povečanje medianega preživetja za 5,5 meseca v kraku s kabozantinibom: mediana (meseci) 26,6 kabozantinib v primerjavi z 21,1 za placebo (HR = 0,85 [95-% IZ: 0,64; 1,12], p = 0,2409).
Endocrine disorders hypothyroidism 
Bolezni endokrinega sistema hipotiroidizem
INFORMATION IN BRAILLE COMETRIQ 20 mg 
PODATKI V BRAILLOVI PISAVI COMETRIQ 20 mg
Juvenile rats (comparable to a >2 year old pediatric population) administered cabozantinib showed increased WBC parameters, decreased haematopoiesis, pubescent/immature female reproductive system (without delayed vaginal opening), tooth abnormalities, reduced bone mineral content and density, liver pigmentation and bile duct hyperplasia. 
Pri mladih podganah (primerljivo z > 2-letno pediatrično populacijo), ki so dobivale kabozantinib, so se pokazali zvišani parametri belih krvnih celic, znižana hematopoeza, pubertetni/nezrel ženski reprodukcijski sistem (brez zakasnitve odpiranja nožnice), nenormalnosti zobovja, zmanjšana mineralna vsebnost in gostota kosti, pigmentacija jeter in hiperplazija žolčevoda.
Female partners of male patients taking cabozantinib must also avoid pregnancy. 
Zanositev morajo preprečiti tudi ženske partnerice moških bolnikov, ki uporabljajo kabozantinib.
Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. 
Ocenili so zaviralno aktivnost kabozantinib pri različnih kinazah in ugotovili, da zavira receptorje MET (receptorski protein za hepatocitni rastni faktor) in VEGF (humani vaskularni endotelijski rastni faktor).
Talk to your doctor or pharmacist before taking COMETRIQ if you: 
Pred začetkom jemanja zdravila COMETRIQ se posvetujte z zdravnikom ali farmacevtom, če:
Because of the potential harm to the infant, mothers should discontinue breast-feeding during treatment with cabozantinib, and for at least 4 months after completing therapy. 
Ker lahko kabozantinib škoduje dojenčku, matere med zdravljenjem s kabozantinibom in še 4 mesece po končanju terapije ne smejo dojiti.
In the 2-year rat carcinogenicity study, cabozantinib-related neoplastic findings consisted of an increased incidence of benign pheochromocytoma, alone or in combination with malignant pheochromocytoma/complex malignant pheochromocytoma of the adrenal medulla in both sexes at exposures well below the intended exposure in humans. 
Neoplastična odkritja 2-letne študije rakotvornosti pri podganah, povezana s kabozantinibom, so izhajala iz povečanega pojava samih benignih feokromocitomov ali v kombinaciji z malignimi feokromocitomi/zapletenimi malignimi feokromocitomi nadledvične sredice pri obeh spolih s precej veliko nižjo izpostavljenostjo, kot je predvidena pri ljudeh.
Dose reductions and dose interruptions occurred in 79% and 72%, respectively, of cabozantinib-treated patients in the pivotal clinical trial. 
V osrednjem kliničnem preskušanju so odmerek zmanjšali pri 79 % bolnikov, njegovo dajanje pa so prekinili pri 72 % bolnikov, zdravljenih s kabozantinibom.
All three subgroups showed increased PFS in the cabozantinib arm compared to the placebo arm (HRs of 0.23, 0.53, and 0.30 for RET mutation positive, negative, and unknown subgroups, respectively). 
Vse tri podskupine so pokazale povečanje PFS v kraku s kabozantinibom v primerjavi s krakom s placebom (HR 0,23 za podskupino s pozitivno mutacijo RET, 0,53 za podskupino z negativno mutacijo RET in 0,30 RET za podskupino s neznano mutacijo RET).
Based on non-clinical safety findings, male and female fertility may be compromised by treatment with cabozantinib (see section 5.3). 
Podatkov o vplivu na plodnost pri ljudeh ni. Na podlagi predkliničnih izsledkov o varnosti lahko zdravljenje s kabozantinibom predstavlja tveganje za plodnost pri moških in ženskah (glejte poglavje 5.3).
A significant improvement in OS was observed in the subgroup of RET M918T mutation positive patients (n=81/219 cabozantinib arm): 44.3 months in the cabozantinib arm vs. 18.9 months in the placebo arm (HR = 0.60, p = 0.0255). 
Značilno izboljšanje OS so opazili za podskupino RET M918T pri bolnikih s pozitivnimi mutacijami (n = 81/219 krak s kabozantinibom): 44,3 meseca v kraku s kabozantinibom oz. 18,9 meseca v kraku s placebom ((HR = 0,60; p = 0,0255).
Concomitant treatment with strong CYP3A4 inhibitors, which may increase cabozantinib plasma concentrations, should be used with caution. 
Pri sočasnem zdravljenju z močnimi zaviralci CYP3A4, ki lahko povečajo koncentracije kabozantiniba v plazmi, je potrebna previdnost.
Cardiac disorders atrial fibrillation angina pectoris, supraventricular tachycardia myocardial infarction 
Srčne bolezni atrijska fibrilacija angina pektoris, supraventrikularna tahikardija miokardni infarkt
Probability amide cleavage product), which possess <1% of the on-target kinase inhibition potency of parent cabozantinib, each represent <10% of total drug-related plasma exposure. 
Verjetnost manjša od < 1 % ciljne učinkovitosti izhodiščnega kabozantiniba, vsak predstavljata < 10 % skupne z zdravilom povezane izpostavljenosti v plazmi.
Cabozantinib should be used with caution in patients who are at risk for, or who have a history of, these events. 
Kabozantinib je treba pri bolnikih, pri katerih obstaja tveganje ali imajo te dogodke v anamnezi, uporabljati previdno.
Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Park, Westboughton, Bolton, Lancashire, BL5 3XX, United Kingdom 
Ime in naslov izdelovalca, odgovornega za sproščanje serij Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Park, Westhoughton, Bolton,
Taking COMETRIQ with food 
Zdravilo COMETRIQ skupaj s hrano
Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp. 
Zato kabozantinib morda lahko poveča koncentracije sočasno uporabljenih substratov P-gp v plazmi.
Results from a study in patients with hepatic impairment indicate that exposure (AUC0-inf) increased by 81% and 63% in subjects with mild and moderate hepatic impairment, respectively (90% CI for AUC0-inf: 121.44% to 270.34% for mild and 107.37% to 246.67% for moderate). 
Rezultati študije pri bolnikih z okvaro jeter kažejo, da se je izpostavljenost (AUC0-inf) povečala za 81 % oz. 63 % pri osebah z blago oz. zmerno jetrno okvaro (90-% IZ za AUC0-inf: 121,44 % do 270,34 % za blago in 107,37 % do 246,67 % za zmerno).
Therefore chronic administration of agents that are strong CYP3A4 inducers with cabozantinib should be avoided (see sections 4.2 and 4.5). 
Zato se je treba kronični sočasni uporabi kabozantiniba in učinkovin, ki so močni induktorji CYP3A4, izogniti (glejte poglavji 4.2 in 4.5).
There are no studies in pregnant women using cabozantinib. 
Študij pri nosečnicah, ki bi uporabljale kabozantinib, niso izvedli.
Subjects should be cautioned regarding taking a P-gp substrate (e.g., fexofenadine, aliskiren, ambrisentan, dabigatran etexilate, digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, tolvaptan) while receiving cabozantinib. 
Osebe, ki jemljejo kabozantinib, je treba opozoriti na uporabo substratov P-gp (npr. feksofenadina, aliskirena, ambrisentana, dabigatran eteksilata, digoksina, kolhicina, maraviroka, posakonazola, ranolazina, saksagliptina, sitagliptina, talinolola, tolvaptana).
Selection of an alternative concomitant medicinal product with no or minimal potential to induce or inhibit CYP3A4 should be considered. 
Razmisliti je treba o sočasni uporabi alternativnih zdravil, ki CYP3A4 ne inducirajo in ne zavirajo ali pa inducirajo in zavirajo le neznatno.
In case of hypertensive crisis, cabozantinib should be discontinued. 
V primeru hipertenzijske krize je treba zdravljenje s kabozantinibom prekiniti.
Cabozantinib is not recommended for use in patients with severe renal impairment as safety and efficacy have not been established in this population. 
Uporaba kabozantiniba se ne priporoča pri bolnikih s hudo ledvično okvaro, saj varnost in učinkovitost pri tej populaciji nista bili dokazani.
• Inflammation of the lips and corners of the mouth 
• vnetje ustnic in ustnih kotičkov
Co-administration of proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with a single dose of 100 mg cabozantinib to healthy volunteers resulted in no clinically-significant effect on plasma cabozantinib exposure (AUC). 
Sočasno dajanje zaviralca protonske črpalke esomeprazola (40 mg na dan za 6 dni), z enkratnim odmerkom 100 mg kabozantiniba, zdravim prostovoljcem ni povzročila klinično značilnih učinkov na izpostavljenost kabozantinibu v plazmi (AUC).
In the event of suspected overdose, cabozantinib should be withheld and supportive care instituted. 
V primeru suma na prevelik odmerek je treba zdravljenje s kabozantinibom ustaviti in uvesti podporno zdravljenje.
Administration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 27 days) to healthy volunteers decreased cabozantinib clearance (by 29%) and increased single-dose plasma cabozantinib exposure (AUC) by 38%. 
Dajanje močnega zaviralca CYP3A4 ketokonazola (400 mg na dan 27 dni) zdravim prostovoljcem je povzročila zmanjšan očistek kabozantiniba (za 29 %) in povečano izpostavljenost kabozantinibu v plazmi po enem odmerku (AUC) za 38 %.
The result of the PFS analysis, based on the central review RECIST assessment, demonstrated a statistically significant difference in the duration of PFS with cabozantinib versus placebo: the median duration was 11.2 months for subjects in the cabozantinib arm versus 4.0 months for subjects in the placebo arm (stratified Hazard Ratio [HR] = 0.28; 95% CI: 0.19, 0.40; p<0.0001; Figure 1). 
Rezultat analize PFS na podlagi ocene centralnega pregleda RECIST je pokazal statistično značilno razliko v trajanju PFS s kabozantinibom v primerjavi s placebom: mediana trajanja je bila 11,2 meseca za osebe v kraku s kabozantinibom v primerjavi s 4,0 meseci za osebe v kraku s placebom (stratificirano razmerje tveganj [HR, hazard ratio] = 0,28; 95-% IZ: 0,19; 0,40; p < 0,0001; slika 1).
• Inflammation in the eye, cataracts 
• vnetje očesa, katarakte
• Fatigue, weakness, headache, dizziness 
• utrujenost, šibkost, glavobol, omotičnost
Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of COMETRIQ therapy. 
Pri obravnavanju suma na neželene reakcije na zdravilo bo morda treba zdravljenje z zdravilom COMETRIQ začasno prekiniti in/ali zmanjšati odmerek.
You should not eat anything for at least 2 hours before taking COMETRIQ and for 1 hour after taking the medicine. 
Vsaj 2 uri, preden vzamete odmerek zdravila COMETRIQ, in 1 uro po uporabi tega zdravila ne smete ničesar jesti.
The most frequent adverse reactions of any grade (experienced by at least 20% of patients) included diarrhoea, PPES, weight decreased, decreased appetite, nausea, fatigue, dysgeusia, hair colour changes, hypertension, stomatitis, constipation, vomiting, mucosal inflammation, asthenia, and dysphonia. 
Najpogostejši neželeni učinki katere koli stopnje (pojavili so se pri vsaj 20 % bolnikov) vključujejo drisko, PPES, zmanjšanje telesne mase, zmanjšanje apetita, navzeo, utrujenost, disgevzijo, spremembe v barvi las, hipertenzijo, stomatitis, konstipacijo, bruhanje, vnetje sluznice, astenijo in disfonijo.
- have had surgery within the last month (or if surgical procedures are planned), including dental procedures - have had radiotherapy in the last 3 months - have inflammatory bowel disease (for example, Crohn's disease or ulcerative colitis or diverticulitis) - have been told that your cancer has spread to your airway or oesophagus - have a recent history of blood clot in the leg, stroke, or heart attack - are taking medicines to control your heart rhythm, have a slow heart rate, have problems with your heart or have problems with the levels of calcium, potassium or magnesium in your blood - have severe liver or kidney disease. 
- ste bili v zadnjih 3 mesecih obsevani, - imate vnetno bolezen črevesja (na primer Crohnovo bolezen ali ulcerozni kolitis ali divertikulitis), - so vam povedali, da se je vaš rak razširil na dihala ali požiralnik, - ste pred kratkim imeli krvni strdek v nogi, možgansko kap ali srčni infarkt, - jemljete zdravila za nadzor srčnega ritma, imate počasen srčni utrip, težave s srcem ali težave z ravnmi kalcija, kalija ali magnezija v krvi, - imate hudo jetrno ali ledvično bolezen.
• Skin ulcers, cysts, red spots on the face or thighs 
• kožne razjede, ciste, rdeče pike na obrazu ali stegnih
However, a trend in increased rate of SAEs has been observed in subjects aged 75 years and older. 
Vendar pa so pri osebah, starih 75 let in več, opazili težnjo k večji pogostnosti resnih neželenih učinkov.
Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models. 
Kabozantinib kaže od odmerka odvisno zaviranje rasti tumorja, regresijo tumorja in/ali zaviranje metastaz v številnih predkliničnih tumorskih modelih.
What COMETRIQ looks like and contents of the pack COMETRIQ 20 mg capsules are grey and have “XL184 20mg” printed on one side. 
Izgled zdravila COMETRIQ in vsebina pakiranja COMETRIQ 20 mg kapsule so sive in imajo na eni strani napis "XL184 20mg".
If there are still 12 hours or more before your next dose is due then take the missed dose as soon as you remember. 
Če ste pozabili vzeti zdravilo COMETRIQ Če je do naslednjega odmerka še 12 ur ali več, vzemite izpuščeni odmerek takoj, ko se spomnite.
COMETRIQ 80 mg capsules are orange and have “XL184 80mg” printed on one side. 
COMETRIQ 80 mg kapsule so oranžne in imajo na eni strani napis "XL184 80mg".
Results from a study in patients with renal impairment indicate that the ratios of geometric LS mean for plasma cabozantinib, Cmax and AUC0-inf were 19% and 30% higher, for subjects with mild renal impairment (90% CI for Cmax 91.60% to 155.51%; AUC0-inf 98.79% to 171.26%) and 2% and 6-7% higher (90% CI for Cmax 78.64% to 133.52%; AUC0-inf 79.61% to 140.11%), for subjects with moderate renal impairment compared to subjects with normal renal function. 
Rezultati študij pri bolnikih z okvaro ledvic kažejo, da so razmerja geometričnega povprečja LS za kabozantinib v plazmi, Cmax in AUC0-inf, za 19 % oz. 30 % višje za osebe z blago okvaro ledvic (90-% IZ za Cmax 91,60 % do 155,51 %; AUC0-inf 98,79 % do 171,26 %) ter 2 % oz. 6 do 7 % višje (90-% IZ za Cmax 78,64 % do 133,52 %; AUC0-inf 79,61 % do 140,11 %), za osebe z zmerno okvaro ledvic v primerjavi z osebami z normalnim delovanjem ledvic.
Blister cards containing either: 
Pretisna zgibanka, ki vsebuje bodisi:
Further, hypospermatogenesis was observe in male dogs at exposure levels below human clinical exposure levels at intended therapeutic dose. 
Nadalje so pri pasjih samcih pri ravneh izpostavljenosti, nižjih, kot so ravni klinične izpostavljenosti pri človeki pri nameravanemu terapevtskemu odmerku, opazili hipospermatogenezo.
Patients who have had recent radiotherapy, have inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, peritonitis, or diverticulitis), have tumour infiltration of trachea, bronchi, or oesophagus, have complications from prior GI surgery (particularly when associated with delayed or incomplete healing), or have complications from prior radiation therapy to the thoracic cavity (including mediastinum) should be carefully evaluated before initiating cabozantinib therapy and subsequently they should be monitored closely for symptoms of perforations and fistulas. 
Bolnike, ki so jih pred kratkim obsevali, imajo vnetno bolezen črevesja (npr. Crohnovo bolezen, ulcerozni kolitis, peritonitis ali divertikulitis), ki imajo tumorsko infiltracijo sapnika, sapnic ali požiralnika, ki so imeli pred gastrointestinalnim posegom zaplete (zlasti v povezavi s poznim ali nepopolnim celjenjem), ali ki imajo zaplete zaradi predhodnega obsevanja prsne votline (vključno z mediastinumom), je treba pred uvedbo zdravljenja s kabozantinibom skrbno oceniti, nato pa natančno spremljati glede pojava simptomov perforacij in fistul.
Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia, hypertension, palmarplantar erythrodysaesthesia syndrome (PPES), and gastrointestinal (GI) events (abdominal or mouth pain, mucosal inflammation, constipation, diarrhoea, vomiting). 
Dogodki, ki se običajno pojavijo zgodaj, vključujejo hipokalciemijo, hipokaliemijo, trombocitopenijo, hipertenzijo, sindrom palmarno-plantarne eritrodisestezije (PPES, palmar-plantar erythrodysaesthesia syndrome) in gastrointestinalni (GI) dogodki (bolečine v trebuhu ali ustih, vnetje sluznice, zaprtje, driska, bruhanje).
When dose reduction is necessary, it is recommended to reduce to 100 mg daily, taken as one 80 mg orange capsule and one 20 mg grey capsule, and then to 60 mg daily, taken as three 20 mg grey capsules. 
Če je treba odmerek zmanjšati, se priporoča zmanjšanje na 100 mg na dan in jemanje ene 80 mg oranžne kapsule in ene 20 mg sive kapsule, nato pa 60 mg na dan, v obliki treh 20 mg sivih kapsul.
The most common laboratory abnormalities were increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased alkaline phosphatase (ALP), lymphopenia, hypocalcaemia, neutropenia, thrombocytopenia, hypophosphataemia, hyperbilirubinemia, hypomagnesaemia, and hypokalaemia. 
Najpogostejše laboratorijske nenormalnosti so bile zvišanje ravni aspartat-aminotransferaze (AST), zvišanje ravni alanin-aminotransferaze (ALT), zvišanje ravni alkalne fosfataze (ALP), limfopenija, hipokalciemija, nevtropenija, trombocitopenija, hipofosfatemija, hiperbilirubinemija, hipomagneziemija in hipokaliemija.
• Liver damage, kidney failure 
• poškodovanje jeter, odpoved ledvic
dabigatran etexilate, digoxin, talinolol, and tolvaptan - Medicines for diabetes, such as saxagliptin and sitagliptin - Medicines used to treat gout, such as colchicine - Medicines used to treat HIV or AIDS, such as ritonavir, maraviroc and emtricitabine - Medicines used to treat viral infections such as efavirenz - Medicines used to prevent transplant rejection (cyclosporine) and cyclosporine-based regimens in rheumatoid arthritis and psoriasis 
ambrisentan, dabigatran eteksilat, digoksin, talinolol in tolvaptan - Zdravila za zdravljenje sladkorne bolezni, kot sta saksagliptin in sitagliptin - Zdravila za zdravljenje protina, kot je kolhicin - Zdravila za zdravljenje okužbe z virusom HIV ali AIDS-a, kot so ritonavir, maravirok in emtricitabin - Zdravila za zdravljenje virusnih okužb, kot je efavirenz - Zdravila za preprečevanje zavrnitve presadka (ciklosporin) in režimi na osnovi ciklosporina pri revmatoidnem artritisu in luskavici